Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas

T. Etrych, A. Braunova, D. Zogala, L. Lambert, N. Renesova, P. Klener

. 2022 ; 14 (3) : . [pub] 20220126

Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc22010143

Grant support
GACR19-01417S Czech Science Foundation
AZV NU21-03-00386 Czech Health Research Council
Center of Excellence UNCE/MED/016 Charles University

Malignant lymphomas represent the most common type of hematologic malignancies. The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT) 131I-tositumomab and 90Y-ibritumomab-tiuxetan. The later clinical success of the first approved antibody-drug conjugate (ADC) for the treatment of lymphomas, anti-CD30 brentuximab vedotin, paved the path for the preclinical development and clinical testing of several other ADCs, including polatuzumab vedotin and loncastuximab tesirine. Other modalities of TDD are based on new formulations of "old" cytostatic agents and their passive trapping in the lymphoma tissue by means of the enhanced permeability and retention (EPR) effect. Currently, the diagnostic and restaging procedures in aggressive lymphomas are based on nuclear imaging, namely PET. A theranostic approach that combines diagnostic or restaging lymphoma imaging with targeted treatment represents an appealing innovative strategy in personalized medicine. The future of theranostics will require not only the capability to provide suitable disease-specific molecular probes but also expertise on big data processing and evaluation. Here, we review the concept of targeted drug delivery in malignant lymphomas from RIT and ADC to a wide array of passively and actively targeted nano-sized investigational agents. We also discuss the future of molecular imaging with special focus on monoclonal antibody-based and monoclonal antibody-derived theranostic strategies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010143
003      
CZ-PrNML
005      
20220425131722.0
007      
ta
008      
220420s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers14030626 $2 doi
035    __
$a (PubMed)35158894
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Etrych, Tomas $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic $1 https://orcid.org/0000000159085182 $7 xx0068504
245    10
$a Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas / $c T. Etrych, A. Braunova, D. Zogala, L. Lambert, N. Renesova, P. Klener
520    9_
$a Malignant lymphomas represent the most common type of hematologic malignancies. The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT) 131I-tositumomab and 90Y-ibritumomab-tiuxetan. The later clinical success of the first approved antibody-drug conjugate (ADC) for the treatment of lymphomas, anti-CD30 brentuximab vedotin, paved the path for the preclinical development and clinical testing of several other ADCs, including polatuzumab vedotin and loncastuximab tesirine. Other modalities of TDD are based on new formulations of "old" cytostatic agents and their passive trapping in the lymphoma tissue by means of the enhanced permeability and retention (EPR) effect. Currently, the diagnostic and restaging procedures in aggressive lymphomas are based on nuclear imaging, namely PET. A theranostic approach that combines diagnostic or restaging lymphoma imaging with targeted treatment represents an appealing innovative strategy in personalized medicine. The future of theranostics will require not only the capability to provide suitable disease-specific molecular probes but also expertise on big data processing and evaluation. Here, we review the concept of targeted drug delivery in malignant lymphomas from RIT and ADC to a wide array of passively and actively targeted nano-sized investigational agents. We also discuss the future of molecular imaging with special focus on monoclonal antibody-based and monoclonal antibody-derived theranostic strategies.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Braunova, Alena $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic $1 https://orcid.org/0000000191536502
700    1_
$a Zogala, David $u Institute of Nuclear Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, 128 08 Prague, Czech Republic $1 https://orcid.org/0000000333721667 $7 xx0121719
700    1_
$a Lambert, Lukas $u Department of Radiology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 128 08 Prague, Czech Republic
700    1_
$a Renesova, Nicol $u First Faculty of Medicine, Institute of Pathological Physiology, Charles University, 121 08 Prague, Czech Republic $1 https://orcid.org/0000000343979469
700    1_
$a Klener, Pavel $u First Faculty of Medicine, Institute of Pathological Physiology, Charles University, 121 08 Prague, Czech Republic $u First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 128 08 Prague, Czech Republic $1 https://orcid.org/0000000177869378 $7 xx0105452
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 14, č. 3 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35158894 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220420 $b ABA008
991    __
$a 20220425131719 $b ABA008
999    __
$a ind $b bmc $g 1784500 $s 1161341
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 3 $e 20220126 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a GACR19-01417S $p Czech Science Foundation
GRA    __
$a AZV NU21-03-00386 $p Czech Health Research Council
GRA    __
$a Center of Excellence UNCE/MED/016 $p Charles University
LZP    __
$a Pubmed-20220420

Find record

Citation metrics

Archiving options